Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

Annexon’s (ANNX) shares jumped 30.8% on Jun 4 after the company announced positive top-line results from its late-stage study evaluating its lead candidate, ANX005, a monoclonal antibody, in patients with Guillain-Barré syndrome (GBS).Per the data readout from the pivotal phase III study, treatment with a single infusion of the 30 mg/kg dose strength of ANX005 met the study's primary endpoint, achieving a highly statistically significant 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8.Tr ...